过渡性B细胞在自身免疫性疾病发病过程中的作用
|
摘要
过渡性B细胞是人体成熟B细胞发育的中间体,近年来研究证实,该过渡性发育阶段是人体对自身反应性B细胞存活与凋亡的关键选择点,因此过渡性B细胞分化机制解析成为自身免疫性疾病发病过程和治疗策略研究的热点问题。本文综述了多发性硬化症、系统性红斑狼疮和原发性干燥综合征发病过程中过渡性B细胞研究的最新进展,为深入探讨自身免疫性疾病发病机制和临床治疗策略提供科学思路。
As the intermediates of mature B cells development in human body,transitional B cells were considered to play a critical role in autoimmune B cell survival or apoptosis recent years,and consequently,the differentiation mechanism of transitional B cells became a hot issue to explore the pathogenesis and treatment strategy of autoimmune diseases. This article reviews the role of transitional B cells in multiple sclerosis,systemic lupus erythematosus and primary Sjogren' s syndrome,and aims to provide a scientific thought for pathogenesis and treatment strategy exploitation of autoimmune diseases.
As the intermediates of mature B cells development in human body,transitional B cells were considered to play a critical role in autoimmune B cell survival or apoptosis recent years,and consequently,the differentiation mechanism of transitional B cells became a hot issue to explore the pathogenesis and treatment strategy of autoimmune diseases. This article reviews the role of transitional B cells in multiple sclerosis,systemic lupus erythematosus and primary Sjogren' s syndrome,and aims to provide a scientific thought for pathogenesis and treatment strategy exploitation of autoimmune diseases.
引文
[1]Pitosa B,Birbach M,Siewiera K,et al.Significant changes in the composition of the precursor B-cell compartment in children less than 2 years old[J].Cytometry B Clin Cytom,2013,84(3):179-186.
[2]Guerrier T,Labalette M,Launay D,et al.Proinflammatory B-cell profile in the early phases of MS predicts an active disease[J].Neurol Neuroimmunol Neuroinflamm,2017,5(2):e431.
[3]Prbstel AK,Sanderson NS,Derfuss T.B cells and autoantibodies in multiple sclerosis[J].Int J Mol Sci,2015,16(7):16576-16592.
[4]Henriques A,Silva I,Inês L,et al.CD38,CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus[J].Clin Exp Med,2016,16(2):227-232.
[5]Pontarini E,Fabris M,Quartuccio L,et al.Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome[J].Rheumatology(Oxford),2015,54(8):1429-1434.
[6]Jacobs HM,Thouvenel CD,Leach S,et al.Cutting Edge:BAFFpromotes autoantibody production via TACI-dependent activation of transitional B cells[J].J Immunol,2016,196(9):3525-3531.
[7]Burton H,Dorling A.Transitional B cell subsets-a convincing predictive biomarker for allograft loss[J].Kidney Int,2017,91(1):18-20.
[8]Sanz I,Lee FE.B cells as therapeutic targets in SLE[J].Nat Rev Rheumatol,2010,6(6):326-337.
[9]Wekerle H.B cells in multiple sclerosis[J].Autoimmunity,2017,50(1):57-60.
[10]Golzari Z,Shabkhiz F,Soudi S,et al.Combined exercise training reduces IFN-γand IL-17 levels in the plasma and the supernatant of peripheral blood mononuclear cells in women with multiple sclerosis[J].Int Immunopharmacol,2010,10(11):1415-1419.
[11]Lee-Chang C,Top I,Zéphir H,et al.Primed status of transitional B cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosis[J].Clin Immunol,2011,139(1):12-20.
[12]Li R,Rezk A,Ghadiri M,et al.Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis[J].J Immunol,2017,198(2):691-698.
[13]Lee-Chang C,Zéphir H,Top I,et al.B-cell subsets up-regulateα4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset[J].Neurosci Lett,2011,487(3):273-277.
[14]Schwab N,Schneider-Hohendorf T,Wiendl H.Therapeutic uses of anti-α4-integrin(anti-VLA-4)antibodies in multiple sclerosis[J].Int Immunol,2015,27(1):47-53.
[15]唐超智,刘晓利,宿俊杰等.淋巴细胞异常在SLE发病机制中的作用研究进展[J].中国免疫学杂志,2015,35(1):135-138.Tang CZ,Liu XL,Su JJ,et al.The role of lymphocyte abnormality in the SLE pathogenesis[J].Chin J Immunol,2015,35(1):135-138.
[16]Wang W,Rangel-Moreno J,Owen T,et al.Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche[J].J Immunol,2014,192(7):3011-3020.
[17]Reth M,Nielsen P.Signaling circuits in early B-cell development[J].Adv Immunol,2014,122(122):129-175.
[18]Landolt-Marticorena C,Wither R,Reich H,et al.Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosus[J].JRheumatol,2011,38(4):642-651.
[19]Ma KY,Li JY,Fang YF,et al.Roles of B cell-intrinsic TLR signals in systemic lupus erythematosus[J].Int J Mol Sci,2015,16(6):13084-13105.
[20]Vossenkmper A,Lutalo PM,Spencer J.Translational mini-review series on B cell subsets in disease transitional B cells in systemic lupus erythematosus and Sj9gren's syndrome:clinical implications and effects of B cell-targeted therapies[J].Clin Exp Immunol,2012,167(1):7-14.
[21]Yadira L,Francisco B,Ezequiel MF,et al.Increased levels of prolactin receptor expression correlate with the early onset of lupus symptoms and increased numbers of transitional-1 B cells after prolactin treatment[J].BMC Immunol,2012,13(11):1-14.
[22]Karlsen M,Jonsson R,Brun JG,et al.TLR-7 and-9 stimulation of peripheral blood B cells indicate altered TLR signalling in primary Sj9gren's syndrome patients by increased secretion of cytokines[J].Scand J Immunol,2015,82(6):523-531.
[23]Brown S,Navarro CN,Pitzalis C,et al.The TRACTISS protocol:a randomised double blind placebo controlled clinical trial of antiB-cell therapy in patients with primary Sj9gren's syndrome[J].BMC Musculoskel Dis,2014,15(21):1-10.
[24]Kroese FG,Abdulahad WH,Haacke E,et al.B-cell hyperactivity in primary Sj9gren's syndrome[J].Expert Rev Clin Immunol,2014,10(4):483-499.
[25]Kadavath S,Bobic S,Efthimiou P.Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sj9gren's syndrome[J].Clin Rheumatol,2015,34(9):1651-1652.
[26]Moreno Torres I,García-Merino A.Anti-CD20 monoclonal antibodies in multiple sclerosis[J].Expert Rev Neurother,2017,17(4):359-371.
[27]Mahevas M,Patin P,Huetz F,et al.B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells[J].JClin Invest,2013,123(1):432-442.
[28]Metzler G,Kolhatkar NS,Rawlings DJ.BCR and co-receptor crosstalk facilitate the positive selection of self-reactive transitional B cells[J].Curr Opin Immunol,2015,37:46-53.
[29]Bertocci B,Lecoeuche D,Sterlin D,et al.Klhl6 deficiency impairs transitional B cell survival and differentiation[J].J Immunol,2017,199(7):2408-2420.
[2]Guerrier T,Labalette M,Launay D,et al.Proinflammatory B-cell profile in the early phases of MS predicts an active disease[J].Neurol Neuroimmunol Neuroinflamm,2017,5(2):e431.
[3]Prbstel AK,Sanderson NS,Derfuss T.B cells and autoantibodies in multiple sclerosis[J].Int J Mol Sci,2015,16(7):16576-16592.
[4]Henriques A,Silva I,Inês L,et al.CD38,CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus[J].Clin Exp Med,2016,16(2):227-232.
[5]Pontarini E,Fabris M,Quartuccio L,et al.Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome[J].Rheumatology(Oxford),2015,54(8):1429-1434.
[6]Jacobs HM,Thouvenel CD,Leach S,et al.Cutting Edge:BAFFpromotes autoantibody production via TACI-dependent activation of transitional B cells[J].J Immunol,2016,196(9):3525-3531.
[7]Burton H,Dorling A.Transitional B cell subsets-a convincing predictive biomarker for allograft loss[J].Kidney Int,2017,91(1):18-20.
[8]Sanz I,Lee FE.B cells as therapeutic targets in SLE[J].Nat Rev Rheumatol,2010,6(6):326-337.
[9]Wekerle H.B cells in multiple sclerosis[J].Autoimmunity,2017,50(1):57-60.
[10]Golzari Z,Shabkhiz F,Soudi S,et al.Combined exercise training reduces IFN-γand IL-17 levels in the plasma and the supernatant of peripheral blood mononuclear cells in women with multiple sclerosis[J].Int Immunopharmacol,2010,10(11):1415-1419.
[11]Lee-Chang C,Top I,Zéphir H,et al.Primed status of transitional B cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosis[J].Clin Immunol,2011,139(1):12-20.
[12]Li R,Rezk A,Ghadiri M,et al.Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis[J].J Immunol,2017,198(2):691-698.
[13]Lee-Chang C,Zéphir H,Top I,et al.B-cell subsets up-regulateα4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset[J].Neurosci Lett,2011,487(3):273-277.
[14]Schwab N,Schneider-Hohendorf T,Wiendl H.Therapeutic uses of anti-α4-integrin(anti-VLA-4)antibodies in multiple sclerosis[J].Int Immunol,2015,27(1):47-53.
[15]唐超智,刘晓利,宿俊杰等.淋巴细胞异常在SLE发病机制中的作用研究进展[J].中国免疫学杂志,2015,35(1):135-138.Tang CZ,Liu XL,Su JJ,et al.The role of lymphocyte abnormality in the SLE pathogenesis[J].Chin J Immunol,2015,35(1):135-138.
[16]Wang W,Rangel-Moreno J,Owen T,et al.Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche[J].J Immunol,2014,192(7):3011-3020.
[17]Reth M,Nielsen P.Signaling circuits in early B-cell development[J].Adv Immunol,2014,122(122):129-175.
[18]Landolt-Marticorena C,Wither R,Reich H,et al.Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosus[J].JRheumatol,2011,38(4):642-651.
[19]Ma KY,Li JY,Fang YF,et al.Roles of B cell-intrinsic TLR signals in systemic lupus erythematosus[J].Int J Mol Sci,2015,16(6):13084-13105.
[20]Vossenkmper A,Lutalo PM,Spencer J.Translational mini-review series on B cell subsets in disease transitional B cells in systemic lupus erythematosus and Sj9gren's syndrome:clinical implications and effects of B cell-targeted therapies[J].Clin Exp Immunol,2012,167(1):7-14.
[21]Yadira L,Francisco B,Ezequiel MF,et al.Increased levels of prolactin receptor expression correlate with the early onset of lupus symptoms and increased numbers of transitional-1 B cells after prolactin treatment[J].BMC Immunol,2012,13(11):1-14.
[22]Karlsen M,Jonsson R,Brun JG,et al.TLR-7 and-9 stimulation of peripheral blood B cells indicate altered TLR signalling in primary Sj9gren's syndrome patients by increased secretion of cytokines[J].Scand J Immunol,2015,82(6):523-531.
[23]Brown S,Navarro CN,Pitzalis C,et al.The TRACTISS protocol:a randomised double blind placebo controlled clinical trial of antiB-cell therapy in patients with primary Sj9gren's syndrome[J].BMC Musculoskel Dis,2014,15(21):1-10.
[24]Kroese FG,Abdulahad WH,Haacke E,et al.B-cell hyperactivity in primary Sj9gren's syndrome[J].Expert Rev Clin Immunol,2014,10(4):483-499.
[25]Kadavath S,Bobic S,Efthimiou P.Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sj9gren's syndrome[J].Clin Rheumatol,2015,34(9):1651-1652.
[26]Moreno Torres I,García-Merino A.Anti-CD20 monoclonal antibodies in multiple sclerosis[J].Expert Rev Neurother,2017,17(4):359-371.
[27]Mahevas M,Patin P,Huetz F,et al.B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells[J].JClin Invest,2013,123(1):432-442.
[28]Metzler G,Kolhatkar NS,Rawlings DJ.BCR and co-receptor crosstalk facilitate the positive selection of self-reactive transitional B cells[J].Curr Opin Immunol,2015,37:46-53.
[29]Bertocci B,Lecoeuche D,Sterlin D,et al.Klhl6 deficiency impairs transitional B cell survival and differentiation[J].J Immunol,2017,199(7):2408-2420.